S&P/ASX 200 Index (ASX: XJO) shares are down 0.9% to 9,049.3 points on Thursday.

Among the 11 market sectors of the ASX 200, healthcare is the only one in the green, up 0.3%.

As earnings season continues, brokers are busy updating their ratings.

Let’s check out some new recommendations.

Neuren Pharmaceuticals Ltd (ASX: NEU)

This ASX healthcare share is $20.60 apiece, up 2.2% today and up 8% over 12 months.

Bell Potter reiterated its buy rating on Neuren Pharmaceuticals shares after the company’s 1H FY26 report.

Neuren Pharmaceuticals announced a maiden fully-franked interim dividend of 15 cents per share.

The broker kept its 12-month share price target at $25.50. 

This implies potential capital gains of almost 25% ahead.

Analyst Thomas Wakim said:

The dividend provides a moderate yield for shareholders, however capital growth will dominate future shareholder returns and is the reason to own the stock in our view, particularly as the binary Phase 3 readout in PMS draws closer (estimated in ~1H CY28), the result of which will largely determine whether NEU is a one-trick pony or whether they repeat the glory a second time round with NNZ-2591.

Whitehaven Coal Ltd (ASX: WHC)

The Whitehaven Coal share price is $8.10, up 0.4% today and up 19% over 12 months.

Morgans downgraded its recommendation from buy to hold due to recent share price strength.

After reviewing the miner’s FY26 results, the broker reduced its 12-month target from $8.50 to $8.05.

This implies the ASX 200 energy share is already fully valued.

Morgans commented:

WHC delivered a mixed result, with EBITDA broadly in line with consensus expectations, although underlying NPAT missed slightly.

A 6c dividend was declared, consistent with consensus.

The effects of poor coal prices in the 1H provided a significant headwind for the full-year result.

FY27 guidance was softer than expected, with production growth appearing limited given the unchanged upper end of group guidance, while both costs and capital expenditure expectations have moved higher.

Endeavour Group Ltd (ASX: EDV)

The Endeavour share price is $3.05, down 0.5% today and down 23% over 12 months.

Morgans maintained a trim call on the ASX 200 consumer staples share after Endeavour’s FY26 report.

The broker cut its target price from $3.20 to $2.95, suggesting a 3% downside ahead.

Morgans said:

There were no major surprises in EDV’s FY26 result after the company pre-announced its key numbers (sales, underlying EBIT and underlying NPAT) in early August.

However, the outlook for costs was greater than anticipated as EDV increases investment to execute its new strategy.

Management noted that competition remains intense in the Retail segment, particularly in the online channel, while Hotels sales growth softened in early 1H27 across all key categories (food & beverage, gaming and accommodation).

We expect FY27 to be a disruptive year as EDV implements its transformation initiatives.

Liquor demand also remains under pressure from elevated interest rates, ongoing cost-of-living pressures and a subdued consumer environment.

Given these headwinds and the execution risk associated with the transformation program, we believe the balance of risks remains skewed to the downside.

The post Buy, hold, sell: Whitehaven, Endeavour, Neuren Pharmaceuticals shares appeared first on The Motley Fool Australia.

More reading

• Neuren Pharmaceuticals reports lower profit but launches first dividend
• Neuren share price in focus after DAYBU wins EU approval for Rett syndrome
• Endeavour Group FY26 profit tumbles despite sales growth
• 5 things to watch on the ASX 200 on Monday
• Buy, hold, sell: Bega Cheese, Temple & Webster and Whitehaven Coal shares after results

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Corporate Travel Management Ltd (ASX: CTD) share price is firmly in the spotlight today after the company reported a resilient FY25 underlying EBITDA of $83.6 million, while also disclosing a statutory net loss after tax of $346.7 million due to significant goodwill write-downs.

What did Corporate Travel Management report?

• FY25 underlying EBITDA: $83.6 million; FY26 forecast: $113.6 million
• Total Transaction Value (TTV): $9.6 billion in FY25 (up from $9.1 billion in FY24); FY26 forecast: $9.8 billion
• Revenue: $643.4 million in FY25; FY26 forecast: $669.9 million
• Statutory net loss after tax: $346.7 million (includes $357.7 million goodwill impairment)
• Strong liquidity: $107 million cash as at 30 June 2026 and new $175 million funding package
• No dividend declared, as remediation and balance sheet strengthening takes priority

What else do investors need to know?

CTM has made significant progress on customer remediation, with around 78% of its $246 million refund program either agreed or close to being finalised. The bulk of settlement payments can be spread through to Q1 FY28, helping manage cash flow.

Governance and risk management have received a major boost, with new board-led oversight, stronger controls, and leadership appointments across legal, commercial, and transformation teams. These changes aim to create a more disciplined and transparent business.

A new strategic initiative, CTM One, focuses on leveraging technology and data—like CTM’s proprietary Lightning and Sleep Space platforms—to drive higher quality growth, better customer outcomes, and stronger operating leverage globally.

What did Corporate Travel Management management say?

Managing Director and CEO Ana Pedersen said:

Today is a significant step forward for CTM and these results demonstrate the resilience of CTM’s underlying business.

Customer remediation is now well advanced, with 78% of refunds agreed or close to finalisation. The recently announced $175 million funding facility provides the certainty and flexibility to complete the process while continuing to support the business. Across our global operations, we continued to retain customers, win new business and grow transaction volumes despite a period of significant disruption.

Our focus is on continuing to deliver for customers, improving operating leverage and building a more connected global business positioned for sustainable long-term growth.

We recognise this has been a challenging period for investors, clients, partners and our people, and we are grateful for their ongoing support and confidence in CTM.

What’s next for Corporate Travel Management?

CTM is preparing for an FY26 earnings recovery, forecasting underlying EBITDA to rise back towards FY24 levels and focusing on disciplined execution of its CTM One strategy. Transaction volumes in early FY27 are tracking in line with expectations, with strong customer retention and new project wins.

As remediation obligations are resolved, restoring the balance sheet, investing in technology, and strengthening the company’s global platform remain core priorities. Dividends may remain suspended in the short term, but more guidance is expected at the upcoming AGM.

View Original Announcement

The post Corporate Travel Management reports FY25 and 1HY26 earnings appeared first on The Motley Fool Australia.

More reading

• Corporate Travel Management secures new funding and updates on FY25 and FY26 earnings
• Corporate Travel Management updates UK remediation progress and settlement terms
• Corporate Travel Management teams up with Amadeus for global tech upgrade
• Corporate Travel Management secures new UK Ministry of Defence contract

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Corporate Travel Management. The Motley Fool Australia has positions in and has recommended Corporate Travel Management. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Clarity Pharmaceuticals Ltd (ASX: CU6) share price is in focus today after the company reported a 68% jump in revenue to $8 million, alongside a net loss of $107.2 million for the year ended 30 June 2026.

What did Clarity Pharmaceuticals report?

• Revenue increased 68% to $8.0 million
• Net loss after tax widened to $107.2 million (up 67%)
• Research and development spend rose to $91.1 million
• Liquid assets grew to $178.3 million at year end
• No dividend declared for FY26
• Net tangible assets per share up to 49.9 cents (from 28.1 cents)

What else do investors need to know?

Clarity raised $203 million in fresh capital through a placement at the end of July 2025, strengthening its cash reserves for future clinical trials and commercialisation. The company received a $9.8 million R&D tax incentive refund, highlighting its ongoing investment in Australian radiopharmaceutical research.

The year was marked by significant clinical progress, with flagship prostate and neuroendocrine tumour imaging and therapy candidates advancing through multiple phase II and phase III trials. Manufacturing and supply agreements were expanded to support the anticipated launch of key products.

What did Clarity Pharmaceuticals management say?

Executive Chair Dr Alan Taylor said:

Our strong progress across clinical, regulatory, and manufacturing activities this year lays the foundation for our transition from developer to commercial stage. We remain focused on bringing innovative diagnostic and therapeutic radiopharmaceuticals to patients globally.

What’s next for Clarity Pharmaceuticals?

Clarity is prioritising late-stage clinical trials and regulatory submissions in the US for its core copper-based SAR technology platform. The company will also focus on building its commercial infrastructure, supported by expanded manufacturing capabilities and new executive appointments.

Looking ahead, Clarity remains well funded and plans to progress new studies targeting unmet needs in cancer care, while preparing for product launches in the US and other key markets.

Clarity Pharmaceuticals share price snapshot

Over the past 12 months, Clarity Pharmaceuticals shares have declined 33%, trailing the All Ordinaries Index (ASX: XAO), which is flat over the same period.

View Original Announcement

The post Clarity Pharmaceuticals FY26 earnings: Revenue jumps, losses widen as clinical pipeline progresses appeared first on The Motley Fool Australia.

More reading

• This ASX biotech is tipped to more than double in value
• Clarity Pharmaceuticals reports clinical trial milestones
• Clarity Pharmaceuticals reports new SECuRE trial responses at higher dose
• Clarity Pharmaceuticals reports clinical progress in June 2026 quarter

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.